0.50Open0.50Pre Close0 Volume275 Open Interest320.00Strike Price0.00Turnover78.61%IV26.23%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.0402Delta0.0027Gamma507.82Leverage Ratio-0.1381Theta0.0025Rho20.39Eff Leverage0.0355Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet